Brooklyn Investment Group Has $280,000 Stock Position in Agilent Technologies, Inc. (NYSE:A)

Brooklyn Investment Group boosted its holdings in shares of Agilent Technologies, Inc. (NYSE:A) by 7.0% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 1,887 shares of the medical research company’s stock after buying an additional 124 shares during the quarter. Brooklyn Investment Group’s holdings in Agilent Technologies were worth $280,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Menard Financial Group LLC lifted its stake in shares of Agilent Technologies by 1.6% during the 2nd quarter. Menard Financial Group LLC now owns 4,845 shares of the medical research company’s stock worth $628,000 after buying an additional 77 shares during the last quarter. McAdam LLC raised its holdings in Agilent Technologies by 3.1% in the 3rd quarter. McAdam LLC now owns 2,531 shares of the medical research company’s stock valued at $376,000 after acquiring an additional 77 shares during the period. Brown Brothers Harriman & Co. lifted its position in Agilent Technologies by 13.5% during the third quarter. Brown Brothers Harriman & Co. now owns 646 shares of the medical research company’s stock worth $96,000 after acquiring an additional 77 shares during the last quarter. Global Retirement Partners LLC boosted its holdings in shares of Agilent Technologies by 3.2% during the third quarter. Global Retirement Partners LLC now owns 2,570 shares of the medical research company’s stock worth $382,000 after acquiring an additional 79 shares during the period. Finally, Rovin Capital UT ADV grew its position in shares of Agilent Technologies by 1.6% in the third quarter. Rovin Capital UT ADV now owns 5,049 shares of the medical research company’s stock valued at $750,000 after purchasing an additional 81 shares during the last quarter.

Insider Buying and Selling at Agilent Technologies

In related news, SVP Dominique Grau sold 9,990 shares of the business’s stock in a transaction on Thursday, September 26th. The shares were sold at an average price of $145.00, for a total transaction of $1,448,550.00. Following the transaction, the senior vice president now owns 40,011 shares in the company, valued at $5,801,595. The trade was a 19.98 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

Agilent Technologies Stock Down 0.1 %

Agilent Technologies stock opened at $134.35 on Wednesday. The firm has a 50 day moving average price of $137.74 and a two-hundred day moving average price of $137.43. The company has a debt-to-equity ratio of 0.36, a quick ratio of 1.37 and a current ratio of 1.78. Agilent Technologies, Inc. has a 52-week low of $124.10 and a 52-week high of $155.35. The firm has a market cap of $38.60 billion, a price-to-earnings ratio of 27.87, a PEG ratio of 5.89 and a beta of 1.07.

Agilent Technologies Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Wednesday, January 22nd. Investors of record on Tuesday, December 31st will be issued a $0.248 dividend. This is a positive change from Agilent Technologies’s previous quarterly dividend of $0.24. The ex-dividend date is Tuesday, December 31st. This represents a $0.99 annualized dividend and a yield of 0.74%. Agilent Technologies’s payout ratio is presently 19.50%.

Wall Street Analysts Forecast Growth

Several analysts recently weighed in on A shares. StockNews.com cut Agilent Technologies from a “buy” rating to a “hold” rating in a report on Tuesday. Wells Fargo & Company initiated coverage on shares of Agilent Technologies in a research note on Tuesday, August 27th. They issued an “overweight” rating and a $157.00 price target on the stock. Barclays lifted their price objective on shares of Agilent Technologies from $135.00 to $145.00 and gave the stock an “underweight” rating in a research note on Tuesday, October 15th. JPMorgan Chase & Co. decreased their target price on shares of Agilent Technologies from $165.00 to $160.00 and set an “overweight” rating on the stock in a research report on Tuesday. Finally, UBS Group raised their target price on shares of Agilent Technologies from $141.00 to $150.00 and gave the stock a “neutral” rating in a report on Thursday, August 22nd. One investment analyst has rated the stock with a sell rating, seven have issued a hold rating and eight have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $144.07.

Agilent Technologies Profile

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.